Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10636596 | 0.87 | MEN1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6056652 | 0.84 | MAOB (0.49) | KMT2ALMNAMAOASMN1; SMN2HTT | |
| SCHEMBL10638902 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL510962 | 0.84 | MEN1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10937278 | 0.84 | RXRA (0.50) | SMN1; SMN2TSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL6147364 | 0.84 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6147369 | 0.83 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3196647 | 0.82 | TSHR (0.54) | CA1CA2CA9MAPTTSHR | |
| SCHEMBL4586654 | 0.79 | TSHR (0.54) | MEN1KMT2ALMNAMAPTTSHR | |
| SCHEMBL10821032 | 0.79 | CA1 (0.69) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324970-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
| US-4766235-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1988-08-23 | — | — | US | disclosed |
| EP-0155940-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985000806-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | CA12 2579/4885CA1 4621/4885CA2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.